

Kathelijn Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1017878/publications.pdf>

Version: 2024-02-01

184
papers

7,338
citations

53751

45
h-index

66879

78
g-index

189
all docs

189
docs citations

189
times ranked

3302
citing authors

#	ARTICLE	IF	CITATIONS
1	Breakthrough bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 413-420.	1.9	295
2	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. <i>Blood</i> , 2013, 121, 4046-4055.	0.6	287
3	The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. <i>Blood</i> , 2002, 99, 2337-2341.	0.6	245
4	Clinical severity of haemophilia A: does the classification of the 1950s still stand?. <i>Haemophilia</i> , 2011, 17, 849-853.	1.0	212
5	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. <i>Blood</i> , 2013, 122, 1129-1136.	0.6	200
6	European principles of haemophilia care. <i>Haemophilia</i> , 2008, 14, 361-374.	1.0	191
7	Consensus perspectives on prophylactic therapy for haemophilia: summary statement. <i>Haemophilia</i> , 2003, 9, 1-4.	1.0	190
8	Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. <i>Haemophilia</i> , 2002, 8, 745-752.	1.0	182
9	Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. <i>Blood</i> , 2012, 119, 612-618.	0.6	181
10	Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 269-275.	1.9	176
11	Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. <i>Haemophilia</i> , 2011, 17, 41-44.	1.0	174
12	Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. <i>Haemophilia</i> , 2011, 17, 2-10.	1.0	170
13	Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. <i>British Journal of Haematology</i> , 2001, 112, 561-565.	1.2	166
14	Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. <i>Haemophilia</i> , 2002, 8, 753-760.	1.0	147
15	Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: A systematic review. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 302-309.	2.3	124
16	Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 730-736.	1.9	115
17	Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. <i>Haemophilia</i> , 2001, 7, 446-452.	1.0	107
18	Inhibitor development in haemophilia according to concentrate. <i>Thrombosis and Haemostasis</i> , 2015, 113, 968-975.	1.8	103

#	ARTICLE	IF	CITATIONS
19	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	18.1	103
20	Can we consider discontinuing primary prophylaxis in adults with severe haemophilia?. Haemophilia, 2008, 14, 10-10.	1.0	92
21	Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia, 2005, 11, 43-48.	1.0	91
22	Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia, 2009, 15, 83-90.	1.0	90
23	Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia, 2001, 7, 544-550.	1.0	86
24	Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia, 2013, 19, 355-361.	1.0	80
25	EUHASS: The European Haemophilia Safety Surveillance system. Thrombosis Research, 2011, 127, S22-S25.	0.8	76
26	Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity. Haemophilia, 2013, 19, 944-950.	1.0	72
27	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 2019, 134, 317-320.	0.6	71
28	What we truly know about occupation as a risk factor for ALS: A critical and systematic review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 295-301.	2.3	69
29	Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood, 2016, 128, 630-637.	0.6	69
30	Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thrombosis and Haemostasis, 2004, 92, 305-310.	1.8	65
31	Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia, 2017, 23, 11-24.	1.0	63
32	Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thrombosis and Haemostasis, 2013, 109, 16-23.	1.8	62
33	Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematology, the, 2017, 4, e75-e82.	2.2	61
34	Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia, 2014, 20, e280-6.	1.0	60
35	Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica, 2020, 106, 123-129.	1.7	60
36	Association of peak factor $\langle \text{sc} \rangle \text{VIII} \langle / \text{sc} \rangle$ levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokineticâ€guided prophylaxis. Haemophilia, 2016, 22, 514-520.	1.0	58

#	ARTICLE	IF	CITATIONS
37	Prophylaxis for severe haemophilia: clinical and economical issues. <i>Haemophilia</i> , 2003, 9, 376-381.	1.0	57
38	Health-related quality of life as outcome parameter in haemophilia treatment. <i>Haemophilia</i> , 2003, 9, 75-82.	1.0	57
39	Coping style and quality of life in patients with epilepsy: a cross-sectional study. <i>Journal of Neurology</i> , 2011, 258, 37-43.	1.8	57
40	Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients. <i>PLoS ONE</i> , 2009, 4, e6745.	1.1	56
41	When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1105-1109.	1.9	54
42	Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. <i>Journal of Hepatology</i> , 2014, 60, 39-45.	1.8	52
43	Review of immune tolerance induction in hemophilia A. <i>Blood Reviews</i> , 2018, 32, 326-338.	2.8	51
44	Treatment for life for severe haemophilia – A cost-utility model for prophylaxis vs. on-demand treatment. <i>Haemophilia</i> , 2013, 19, e228-38.	1.0	48
45	Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. <i>British Journal of Haematology</i> , 2016, 174, 454-460.	1.2	46
46	LASER-ASSISTED ENDOSCOPIC THIRD VENTRICULOSTOMY. <i>Neurosurgery</i> , 2008, 62, 437-444.	0.6	42
47	Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List (<sc>p</sc>ed<sc>hal</sc>). <i>Haemophilia</i> , 2010, 16, 281-289.	1.0	42
48	Quality of life of caregivers of patients with intractable epilepsy. <i>Epilepsia</i> , 2009, 50, 1294-1296.	2.6	41
49	Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. <i>Haemophilia</i> , 2011, 17, 433-438.	1.0	41
50	Value of routine ultrasound in detecting early joint changes in children with haemophilia using the “Haemophilia Early Arthropathy Detection with UltraSound”™ protocol. <i>Haemophilia</i> , 2016, 22, 121-125.	1.0	41
51	Magnetic resonance imaging in teenagers and young adults with limited haemophilic arthropathy: baseline results from a prospective study. <i>Haemophilia</i> , 2011, 17, 926-930.	1.0	38
52	Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. <i>Haemophilia</i> , 2012, 18, e241-6.	1.0	36
53	Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. <i>Thrombosis and Haemostasis</i> , 2016, 115, 931-938.	1.8	36
54	Monitoring joint health in haemophilia: Factors associated with deterioration. <i>Haemophilia</i> , 2017, 23, 934-940.	1.0	36

#	ARTICLE	IF	CITATIONS
55	Hepatitis C and health-related quality of life among patients with hemophilia. <i>Haematologica</i> , 2005, 90, 846-50.	1.7	36
56	Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed. <i>Haemophilia</i> , 2016, 22, 142-147.	1.0	35
57	Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. <i>Haemophilia</i> , 2008, 14, 196-201.	1.0	34
58	Habitual physical activity in Dutch children and adolescents with haemophilia. <i>Haemophilia</i> , 2011, 17, e906-12.	1.0	34
59	Coping style and health-related quality of life in caregivers of epilepsy patients. <i>Journal of Neurology</i> , 2011, 258, 1788-1794.	1.8	33
60	Comparing findings of routine Haemophilia Joint Health Score and Haemophilia Early Arthropathy Detection with UltraSound assessments in adults with haemophilia. <i>Haemophilia</i> , 2017, 23, e141-e143.	1.0	33
61	BAY 94â€9027, a PEGylated recombinant factor VIII, exhibits a prolonged halfâ€life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies. <i>Haemophilia</i> , 2018, 24, 733-740.	1.0	33
62	Unravelling adherence to prophylaxis in haemophilia: a patientsâ€™ perspective. <i>Haemophilia</i> , 2015, 21, 612-621.	1.0	32
63	Association between joint bleeds and pettersson scores in severe haemophilia. <i>Acta Radiologica</i> , 2002, 43, 528-532.	0.5	31
64	Learning intravenous infusion in haemophilia: experience from the Netherlands. <i>Haemophilia</i> , 2012, 18, 516-520.	1.0	31
65	Promoting selfâ€management and adherence during prophylaxis: evidenceâ€based recommendations for haemophilia professionals. <i>Haemophilia</i> , 2016, 22, 499-506.	1.0	31
66	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. <i>Thrombosis and Haemostasis</i> , 2017, 117, 508-518.	1.8	31
67	A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. <i>Haematologica</i> , 2011, 96, 738-743.	1.7	30
68	The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. <i>Haemophilia</i> , 2013, 19, 35-43.	1.0	29
69	Haemophilia Joint Health Score in healthy adults playing sports. <i>Haemophilia</i> , 2014, 20, 282-286.	1.0	29
70	Evaluating outcome of prophylaxis in haemophilia: objective and selfâ€reported instruments should be combined. <i>Haemophilia</i> , 2016, 22, e80-e86.	1.0	29
71	Primary prophylaxis in haemophilia care: Guideline update 2016. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 81-85.	0.6	29
72	Diagnostic accuracy of pointâ€ofâ€care ultrasound for evaluation of early bloodâ€induced joint changes: Comparison with <sc>MRI</sc>. <i>Haemophilia</i> , 2018, 24, 971-979.	1.0	29

#	ARTICLE	IF	CITATIONS
73	MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia. <i>Blood Advances</i> , 2020, 4, 113-121.	2.5	29
74	Effects of Vaginal Prolapse Surgery on Sexuality in Women and Men; Results from a RCT on Repair With and Without Mesh. <i>Journal of Sexual Medicine</i> , 2012, 9, 1200-1211.	0.3	28
75	How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. <i>Haemophilia</i> , 2015, 21, 444-450.	1.0	28
76	Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B&YOND extension study. <i>Haemophilia</i> , 2020, 26, e262-e271.	1.0	28
77	Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. <i>Haematologica</i> , 2015, 100, e84-e86.	1.7	27
78	Protected by nature? Effects of strenuous physical exercise on FVIII activity in moderate and mild haemophilia A patients: a pilot study. <i>Haemophilia</i> , 2013, 19, 519-523.	1.0	26
79	International cross-cultural validation study of the Canadian Haemophilia Outcomes: Kids™ Life Assessment Tool. <i>Haemophilia</i> , 2015, 21, 351-357.	1.0	26
80	The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis. <i>Haemophilia</i> , 2016, 22, 833-840.	1.0	26
81	Safety, efficacy and pharmacokinetics of rVIII^{SC} in children with severe hemophilia A: results of a multicenter clinical trial. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 636-644.	1.9	26
82	Prophylaxis for Severe Hemophilia: Experience from Europe and the United States. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 049-054.	1.5	25
83	Assessments of outcome in haemophilia – what is the added value of QoL tools?. <i>Haemophilia</i> , 2015, 21, 430-435.	1.0	25
84	Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?. <i>Blood Transfusion</i> , 2013, 11, 364-9.	0.3	25
85	Prophylaxis for adults with haemophilia: one size does not fit all. <i>Blood Transfusion</i> , 2012, 10, 169-73.	0.3	25
86	The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. <i>Transfusion</i> , 2006, 46, 1360-1366.	0.8	24
87	Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. <i>Haemophilia</i> , 2007, 14, 071115150757005-???	1.0	24
88	Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. <i>Haemophilia</i> , 2010, 16, 71-79.	1.0	24
89	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. <i>Haematologica</i> , 2017, 102, 1486-1493.	1.7	24
90	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. <i>Haemophilia</i> , 2018, 24, 283-290.	1.0	24

#	ARTICLE	IF	CITATIONS
91	European principles of care for women and girls with inherited bleeding disorders. <i>Haemophilia</i> , 2021, 27, 837-847.	1.0	23
92	Prophylaxis in real life scenarios. <i>Haemophilia</i> , 2014, 20, 106-113.	1.0	22
93	Scoring haemophilic arthropathy on X-rays: improving inter- and intra-observer reliability and agreement using a consensus atlas. <i>European Radiology</i> , 2016, 26, 1963-1970.	2.3	21
94	Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. <i>Haemophilia</i> , 2018, 24, e33-e49.	1.0	21
95	PROTECT VIII Kids: BAY 94â€9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A. <i>Haemophilia</i> , 2020, 26, e55-e65.	1.0	20
96	Patientâ€™relevant health outcomes for hemophilia care: Development of an international standard outcomes set. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12488.	1.0	20
97	Dose and outcome of care in haemophilia - how do we define cost-effectiveness?. <i>Haemophilia</i> , 2004, 10, 216-220.	1.0	19
98	Functional limitations in <sc>R</sc>omanian children with haemophilia: further testing of psychometric properties of the <sc>P</sc>aediatric <sc>H</sc>aemophilia <sc>A</sc>ctivities <sc>L</sc>ist. <i>Haemophilia</i> , 2013, 19, e116-25.	1.0	19
99	Longâ€™term effects of joint bleeding before starting prophylaxis in severe haemophilia. <i>Haemophilia</i> , 2016, 22, 852-858.	1.0	19
100	Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1395-1406.	1.6	19
101	RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia. <i>Haemophilia</i> , 2007, 13, 345-350.	1.0	18
102	Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A. <i>Haemophilia</i> , 2010, 16, 892-901.	1.0	18
103	Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A. <i>Haemophilia</i> , 2015, 21, 227-233.	1.0	18
104	Requirements for immune recognition and processing of factor VIII by antigen-presenting cells. <i>Blood Reviews</i> , 2012, 26, 43-49.	2.8	17
105	Sports participation and sports injuries in Dutch boys with haemophilia. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2020, 30, 1256-1264.	1.3	17
106	Models of prophylaxis. <i>Haemophilia</i> , 2012, 18, 136-140.	1.0	16
107	Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediateâ€™and highâ€™dose prophylaxis. <i>Haemophilia</i> , 2019, 25, 244-251.	1.0	16
108	Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: Results of an International Prophylaxis Study Group global survey. <i>Haemophilia</i> , 2020, 26, 685-693.	1.0	16

#	ARTICLE	IF	CITATIONS
109	The factor VIII treatment history of non-severe hemophilia A. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3203-3210.	1.9	15
110	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. <i>Blood Advances</i> , 2022, 6, 902-908.	2.5	15
111	Inhibitor development in non-severe haemophilia across Europe. <i>Thrombosis and Haemostasis</i> , 2015, 114, 670-675.	1.8	14
112	Achieving self-management of prophylactic treatment in adolescents: The case of haemophilia. <i>Patient Education and Counseling</i> , 2016, 99, 1179-1183.	1.0	14
113	Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 868-875.	1.9	14
114	Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. <i>Haemophilia</i> , 2020, 26, 1072-1080.	1.0	14
115	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. <i>Haemophilia</i> , 2021, 27, 876-885.	1.0	14
116	Estimating unknown parameters in haemophilia using expert judgement elicitation. <i>Haemophilia</i> , 2013, 19, e282-8.	1.0	13
117	Targeting Factor Replacement Therapy in Severe Hemophilia: Which Level Is Important?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 860-863.	1.5	13
118	Defining adherence to prophylaxis in haemophilia. <i>Haemophilia</i> , 2016, 22, e311-4.	1.0	13
119	Low-dose prophylaxis for severe haemophilia: a little goes a long way. <i>Haemophilia</i> , 2016, 22, 331-333.	1.0	13
120	Association between joint bleeds and Pettersson scores in severe haemophilia. <i>Acta Radiologica</i> , 2002, 43, 528-32.	0.5	13
121	Do the SIPPET study results apply to the patients I treat?. <i>Haemophilia</i> , 2017, 23, 348-349.	1.0	12
122	Impact of prophylaxis on health-related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 397-404.	1.0	12
123	The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1626-1636.	1.9	12
124	Assessing the test-retest reliability and smallest detectable change of the Haemophilia Activities List. <i>Haemophilia</i> , 2021, 27, 108-112.	1.0	12
125	Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1896-1906.	1.9	12
126	<sc>FVIII</sc> inhibitor development according to concentrate: data from the <sc>EUHASS</sc> registry excluding overlap with other studies. <i>Haemophilia</i> , 2016, 22, e36-8.	1.0	11

#	ARTICLE	IF	CITATIONS
127	Imaging of haemophilic arthropathy: Awareness of pitfalls and need for standardization. <i>Haemophilia</i> , 2017, 23, 645-647.	1.0	11
128	Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. <i>Blood Advances</i> , 2021, 5, 2732-2739.	2.5	11
129	The European Haemophilia Network (EUHANET). <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s515-8.	0.3	11
130	Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. <i>British Journal of Haematology</i> , 2017, 178, 20-31.	1.2	10
131	Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1690-1700.	1.8	10
132	<p>The Perspectives of Adolescents and Young Adults on Adherence to Prophylaxis in Hemophilia: A Qualitative Study</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 163-171.	0.8	10
133	The Paediatric Haemophilia Activities List (pedHAL) in routine assessment: changes over time, child-parent agreement and informative domains. <i>Haemophilia</i> , 2019, 25, 953-959.	1.0	9
134	Health-related quality of life. The effect of pelvic floor muscle training and midurethral sling surgery: a systematic review. <i>International Urogynecology Journal</i> , 2012, 23, 1155-1162.	0.7	8
135	Evidence for and cost-effectiveness of physiotherapy in haemophilia: a Dutch perspective. <i>Haemophilia</i> , 2016, 22, 943-948.	1.0	8
136	Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. <i>Haemophilia</i> , 2016, 22, e375-82.	1.0	8
137	Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. <i>Haemophilia</i> , 2018, 24, e280-e283.	1.0	8
138	A feasibility study on two tailored interventions to improve adherence in adults with haemophilia. <i>Pilot and Feasibility Studies</i> , 2020, 6, 189.	0.5	8
139	PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 949027 (damoctocog alfa pegol) in children with severe haemophilia A. <i>Haemophilia</i> , 2021, 27, 434-444.	1.0	8
140	Adherence to prophylaxis and its association with activation of self-management and treatment satisfaction. <i>Haemophilia</i> , 2021, 27, 581-590.	1.0	8
141	Quality of haemophilia care in The Netherlands: new standards for optimal care. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s501-4.	0.3	8
142	Generic PROMIS item banks in adults with hemophilia for patient-reported outcome assessment: Feasibility, measurement properties, and relevance. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12621.	1.0	8
143	Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia. <i>Thrombosis and Haemostasis</i> , 2000, 84, 977-80.	1.8	8
144	Starreveld scoring method in diagnosing childhood constipation. <i>Pediatric Radiology</i> , 2010, 40, 1789-1793.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 115-20.	1.4	7
146	Determinants of participation in patients with severe haemophilia. <i>Haemophilia</i> , 2012, 18, 860-867.	1.0	7
147	Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. <i>Thrombosis and Haemostasis</i> , 2022, 122, 208-215.	1.8	7
148	Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A. <i>HemaSphere</i> , 2022, 6, e679.	1.2	7
149	NO PROTECTIVE EFFECT OF BREASTFEEDING ON INHIBITOR FORMATION IN SEVERE HEMOPHILIA. <i>Pediatric Hematology and Oncology</i> , 2005, 22, 575-580.	0.3	6
150	Sports participation of patients with haemophilia in the COVID-19 era: The Dutch experience. <i>Haemophilia</i> , 2021, 27, e295-e297.	1.0	6
151	Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items. <i>Haemophilia</i> , 2021, 27, 1062-1070.	1.0	6
152	Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis. <i>Thrombosis and Haemostasis</i> , 2008, 99, 965-965.	1.8	5
153	Pathophysiological Mechanisms of Endogenous FVIII Release following Strenuous Exercise in Non-severe Haemophilia: A Review. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2237-2242.	1.8	5
154	Incidence and Outcome of Discontinuation of Prophylactic Treatment among Young Adults with Severe Hemophilia.. <i>Blood</i> , 2004, 104, 3086-3086.	0.6	5
155	Detecting low blood concentrations in joints using T1 and T2 mapping at 1.5, 3, and 7 T: an in vitro study. <i>European Radiology Experimental</i> , 2021, 5, 51.	1.7	5
156	Positioning extended half-life concentrates for future use: a practical proposal. <i>Haemophilia</i> , 2018, 24, e369-e372.	1.0	4
157	Novel <i>F8</i> and <i>F9</i> gene variants from the PedNet hemophilia registry classified according to ACMG/AMP guidelines. <i>Human Mutation</i> , 2020, 41, 2058-2072.	1.1	4
158	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. <i>Haemophilia</i> , 2020, 26, 966-974.	1.0	4
159	A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy. <i>Haemophilia</i> , 2021, 27, e675-e682.	1.0	4
160	Variability in Bleeding Pattern of Severe Hemophilia.. <i>Blood</i> , 2004, 104, 3094-3094.	0.6	4
161	Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis. <i>Blood</i> , 2014, 124, 689-689.	0.6	4
162	Adherence to prophylaxis and bleeding in children: Significant drop during puberty but no correlation with bleeding. <i>Haemophilia</i> , 2020, 26, e240-e243.	1.0	3

#	ARTICLE	IF	CITATIONS
163	Shortening the paediatric Haemophilia Activities List (pedHAL) based on pooled data from international studies. <i>Haemophilia</i> , 2021, 27, 305-313.	1.0	3
164	Sports participation is not associated with adherence to prophylaxis in Dutch patients with haemophilia. <i>Haemophilia</i> , 2021, 27, e402-e405.	1.0	3
165	Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 724-734.	1.5	3
166	Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis. <i>Blood</i> , 2016, 128, 2576-2576.	0.6	3
167	Limits of agreement between raters are required for the use of <scp>HHS</scp> 2.1 in clinical studies. <i>Haemophilia</i> , 2015, 21, e70-1.	1.0	2
168	Selfâ€infusion of prophylaxis: evaluating the quality of its performance and time needed. <i>Haemophilia</i> , 2016, 22, e214-7.	1.0	2
169	Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions. <i>Haemophilia</i> , 2018, 24, 177-179.	1.0	2
170	Comparison between coagulation factor VIII quantified with oneâ€stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 819-826.	0.7	2
171	Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A. <i>HemaSphere</i> , 2021, 5, e557.	1.2	2
172	BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study. <i>Blood</i> , 2020, 136, 40-41.	0.6	2
173	Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc. <i>TH Open</i> , 2020, 04, e362-e364.	0.7	2
174	Bone mineral density in haemophilia â€ a multicentre study evaluating the impact of different replacement regimens. <i>Haemophilia</i> , 2022, 28, 239-246.	1.0	2
175	A tailored intervention for illness acceptance improves adherence and quality of life in adults with haemophilia using prophylaxis. <i>Haemophilia</i> , 2021, 27, e434-e440.	1.0	1
176	Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. <i>Blood</i> , 2014, 124, 2818-2818.	0.6	1
177	No Association Between Platelet Function and Hemophilia B Phenotype. <i>Blood</i> , 2014, 124, 4994-4994.	0.6	1
178	Not All Patients Benefit from Switching to Eh!: Results from the Wapps Database. <i>Blood</i> , 2020, 136, 21-22.	0.6	1
179	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. <i>HemaSphere</i> , 2022, 6, e694.	1.2	1
180	Cost Effectiveness Analysis Evaluating Factor Viii As Primary Prophylaxis Treatment for Patients With Severe Haemophilia A In the Netherlands. <i>Value in Health</i> , 2014, 17, A531.	0.1	0

#	ARTICLE	IF	CITATIONS
181	No Relation between Platelet Activity and Haemophilia B Phenotype. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1481-1483.	1.8	0
182	Protected by Nature: Effects of Exercise In Non-Severe Haemophilia Patients. <i>Blood</i> , 2010, 116, 545-545.	0.6	0
183	Multiple joint procedures in haemophilia: benefit of self-reported activities. <i>The Journal of Haemophilia Practice</i> , 2016, 3, 55-61.	0.2	0
184	Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study. <i>Blood</i> , 2016, 128, 3774-3774.	0.6	0